Partial Parallelism and Partial Blockade by Bryostatin 1 of Effects of Phorbol Ester Tumor Promoters on Primary Mouse Epidermal Cells
Overview
Authors
Affiliations
Bryostatin 1, a macrocyclic lactone, functions like the phorbol esters biochemically in binding to and activating protein kinase C. Biologically, however, although it induces some phorbol ester responses such as mitogenesis in Swiss 3T3 cells, it paradoxically blocks the effects of the phorbol esters on differentiation in HL-60 promyelocytic leukemia cells and Friend erythroleukemia cells. Since the phorbol esters induce proliferation and terminal differentiation in distinct subpopulations of epidermal basal cells, we have now examined the action of bryostatin 1 in that system. Bryostatin 1 decreased epidermal growth factor binding and induced ornithine decarboxylase activity, the latter a marker of proliferation. The magnitude of the maximal induction of ornithine decarboxylase was less than for phorbol 12,13-dibutyrate. Bryostatin 1 only transiently caused the morphological change typical of phorbol ester treatment and did not induce transglutaminase or cornified envelope production, markers of the differentiative pathway. Combined treatment with bryostatin 1 and phorbol 12,13-dibutyrate gave similar results to treatment with bryostatin 1 alone, i.e., slight reduction to complete inhibition of phorbol ester action, depending on the response. The mechanism may reflect time dependent block of the protein kinase C pathway by bryostatin 1 in this system; although bryostatin 1 inhibited epidermal growth factor binding at short incubation times (1-2 h), by 4 h of incubation its inhibition was markedly reduced and it correspondingly blocked inhibition of epidermal growth factor binding by phorbol 12,13-dibutyrate. Since induction of terminal differentiation is proposed to be an essential component of phorbol ester mediated tumor promotion in skin, our findings suggest that bryostatin 1 may function as an inhibitor of phorbol ester promotion.
KLF4 Inhibits the Activation of Human Hepatic Stellate Cell In Vitro.
Yang X, Chen Z, Tan J, Xue Y, Zheng H Curr Med Sci. 2024; 44(3):512-518.
PMID: 38789819 DOI: 10.1007/s11596-024-2860-8.
Structural insights into C1-ligand interactions: Filling the gaps by in silico methods.
Katti S, Igumenova T Adv Biol Regul. 2021; 79:100784.
PMID: 33526356 PMC: 8867786. DOI: 10.1016/j.jbior.2020.100784.
Zuo L, Li J, Ge S, Ge Y, Shen M, Wang Y J Cell Mol Med. 2019; 23(8):5588-5599.
PMID: 31251471 PMC: 6652299. DOI: 10.1111/jcmm.14457.
Synthesis and Biological Evaluation of Fluorescent Bryostatin Analogues.
Cummins T, Kedei N, Czikora A, Lewin N, Kirk S, Petersen M Chembiochem. 2018; 19(8):877-889.
PMID: 29424951 PMC: 6980389. DOI: 10.1002/cbic.201700655.
Biological activity of the bryostatin analog Merle 23 on mouse epidermal cells and mouse skin.
Kelsey J, Cataisson C, Chen J, Herrmann M, Petersen M, Baumann D Mol Carcinog. 2016; 55(12):2183-2195.
PMID: 26859836 PMC: 7751955. DOI: 10.1002/mc.22460.